UCB logo
UCB
UCBJY | OTC
Chart Builder DCF Calculator
$161.62
-$2.13 (-1.30%)
At close: Nov 16, 2026, 3:59 PM ET
$161.62
$0.00 (0.00%)
After-hours: Nov 16, 2026, 3:59 PM ET

UCB Company Profile

Company profile explained

Company Profile

UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases. Its primary product, Cimzia, addresses a spectrum of inflammatory TNF-mediated conditions, encompassing ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For epilepsy management, the company provides Vimpat, Keppra, and Briviact, alongside Nayzilam, an emergency nasal spray for seizure clusters. Neupro is offered for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal alleviate allergy symptoms. The portfolio further extends to Evenity, a treatment for osteoporosis in postmenopausal women, and BIMZELX, used for psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Dapirolizumab pegol is also available for systemic lupus erythematosus. UCB maintains a robust development pipeline featuring therapies such as rozanolixizumab for myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for stereotypic prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Additionally, the company engages in contract manufacturing services. UCB S.A. has forged collaborative agreements with partners including Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. Its operational presence spans the United States, Japan, Germany, a broader European footprint (including Spain, France, Italy, the United Kingdom, and Ireland), China, Belgium, and other global territories. Incorporated in 1925, the company's headquarters are situated in Brussels, Belgium.

Key Executives

Name Position
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Alistair Henry Executive Vice President & Chief Scientific Officer
Caroline Vancoillie Chief Accounting Officer & Head of Group Finance
Denelle J. Waynick Johnson Executive Vice President & General Counsel
Emmanuel Caeymaex Executive VP & Head of Patient Evidence
Fiona Du Monceau Executive VP of Patient Impact & Chief Commercial Officer
Gwendoline Ornigg Head of Global Corporate Communication
Jean-Luc Fleurial Executive Vice President & Chief Human Resources Officer
Raf Remijsen Head of Treasury & Risk Management
Sandrine Dufour Executive VP & CFO
Veronique Toully Head of Sustainability, Corporate Affairs & Enterprise Risk Management
Xavier Michel VP & Group Secretary General
UCB
UCB logo
Country Belgium
IPO Date Aug 3, 2012
Industry Biotechnology
Sector Healthcare
Employees 10,117
CEO Jean-Christophe Tellier

Contact Details

Allée de la Recherche, 60 Brussels, BU 1070 Belgium

Stock Details

Ticker Symbol UCBJY
Exchange OTC
Fiscal Year n/a
Reporting Currency USD
CIK Code n/a
CUSIP Number 903480101
ISIN Number US9034801012
SIC Code n/a

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.